By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AstraZeneca PLC 

15 Stanhope Gate

London  England  W1K 1LN  United Kingdom
Phone: 44-20-7304-5000 Fax: 44-20-7304-5151


AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.




CEO: Pascal Soriot

CFO: Marc Dunoyer

CMO: Marc Dunoyer

CTO: Andrew Chen

CCO: Katarina Ageborg

CMO: Sean Bohen


Please click here for clinical trial information.


Please click here for AstraZeneca job opportunities.


AstraZeneca Medications

For more information, visit and follow us on


Key Statistics

Ownership: Public

Web Site: AstraZeneca PLC
Employees: 50,000 worldwide
Symbol: AZN

Company News
Why AstraZeneca PLC (AZN)'s 'Big Pipeline' Makes It A Possible Take-Out Candidate 9/22/2017 6:34:46 AM
GlaxoSmithKline (GSK), AstraZeneca PLC (AZN) And Labcyte Inc. Form Alliance To Develop Acoustic Mass Spectrometry - A Novel Sample Handling Technology For MS-Based Drug Discovery 9/20/2017 6:07:19 AM
Adherium Releases Next Generation Adherence Monitor, Smartturbo Model 4, For AstraZeneca PLC (AZN)’s Turbuhaler 9/15/2017 10:14:26 AM
AstraZeneca PLC (AZN) Release: Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile And Fewer CV Events In Patients With Type-2 Diabetes At Wide Range Of CV Risk 9/15/2017 7:18:44 AM
Massachusetts' Flexion (FLXN) Terminates R&D Deal With AstraZeneca PLC (AZN) 9/15/2017 5:53:53 AM
AstraZeneca PLC (AZN) Offloads Remaining Anesthetics Portfolio in $766 Million Deal 9/14/2017 5:32:58 AM
Biogen (BIIB) Notches An AstraZeneca PLC (AZN) Vet For Its Payroll 9/12/2017 6:05:57 AM
AstraZeneca PLC (AZN)’s Tagrisso (Osimertinib) Shows Potential As A New Standard Of Care In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer At ESMO 2017 Congress 9/11/2017 8:55:50 AM
AstraZeneca PLC (AZN) Presents New Results Identifying Severe Asthma Patients Who Would Benefit Most From Benralizuma 9/11/2017 8:41:13 AM
AstraZeneca PLC (AZN)'s Tagrisso Shows Potential As A New Standard Of Care In First-Line EGFR-Mutated Lung Cancer At ESMO 2017 Congress 9/11/2017 7:30:12 AM